This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
RHHBYNegative Net Change NVONo Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
by Zacks Equity Research
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
BMYNegative Net Change MRKNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
by Zacks Equity Research
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
GILDNegative Net Change JAZZNegative Net Change AXSMNegative Net Change KRYSNegative Net Change
biotechs
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
by Zacks Equity Research
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
GSKPositive Net Change ALNYPositive Net Change OPTNNo Net Change SAVANegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
by Zacks Equity Research
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.
AZNNegative Net Change NVONo Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
by Zacks Equity Research
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
GSKPositive Net Change ANIPNegative Net Change CTMXNegative Net Change ETNBPositive Net Change
biotechs medical pharmaceuticals vaccines
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
BIIBNegative Net Change LLYNegative Net Change GILDNegative Net Change SAVANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
SNYPositive Net Change ANIPNegative Net Change CTMXNegative Net Change ETNBPositive Net Change
biotechs medical pharmaceuticals
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation
by Zacks Equity Research
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
NVONo Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
by Zacks Equity Research
ALKS' set of proprietary products, Vivitrol, Aristada and Lybalvi, is driving the top-line. However, stiff competition in the target remains a woe.
DVAXNegative Net Change ALKSNegative Net Change GILDNegative Net Change KRYSNegative Net Change
biotechs
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
by Zacks Equity Research
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
NVONo Net Change LLYNegative Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
REGNNegative Net Change DVAXNegative Net Change GILDNegative Net Change UBXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
SNYPositive Net Change ANIPNegative Net Change CTMXNegative Net Change ETNBPositive Net Change
biotechs medical pharmaceuticals
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
by Ekta Bagri
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
JNJNegative Net Change ACIUNegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
by Zacks Equity Research
The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
GSKPositive Net Change DVAXNegative Net Change GILDNegative Net Change KRYSNegative Net Change
biotechs
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
RHHBYNegative Net Change NVONo Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
by Tirthankar Chakraborty
Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?
PFENegative Net Change
biotechs medical oncology-screening
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
by Sundeep Ganoria
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
RHHBYNegative Net Change SRPTPositive Net Change PTCTNegative Net Change ARWRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
by Zacks Equity Research
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
NVSPositive Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
by Zacks Equity Research
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
ANIPNegative Net Change CTMXNegative Net Change ETNBPositive Net Change ELEVNegative Net Change
biotechs medical
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
by Zacks Equity Research
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
ALNYPositive Net Change NVSPositive Net Change DVAXNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
DVAXNegative Net Change GILDNegative Net Change OPTNNo Net Change ARVNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.
DVAXNegative Net Change GILDNegative Net Change PCRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
by Zacks Equity Research
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
DVAXNegative Net Change GILDNegative Net Change ARVNNegative Net Change MIRMNegative Net Change
biotechs
GILD Stock Down on Report of Cut in HIV Prevention Spending
by Zacks Equity Research
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
GSKPositive Net Change PFENegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals